These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 8103618)
21. Parallels between neuroleptic effects and lethargic encephalitis: the production of dyskinesias and cognitive disorders. Breggin PR Brain Cogn; 1993 Sep; 23(1):8-27. PubMed ID: 8105824 [TBL] [Abstract][Full Text] [Related]
24. Neuroleptic-induced reinnervation sprouting in the central nervous system (a model for the development of tardive dyskinesia and supersensitivity psychosis). Staton RD; Brumback RA J Clin Psychiatry; 1980 Dec; 41(12 Pt 1):427-8. PubMed ID: 6108320 [No Abstract] [Full Text] [Related]
25. Dyskinetic movement disorder among adults with mental retardation: phenomenology and co-occurrence with stereotypy. Bodfish JW; Newell KM; Sprague RL; Harper VN; Lewis MH Am J Ment Retard; 1996 Sep; 101(2):118-29. PubMed ID: 8883667 [TBL] [Abstract][Full Text] [Related]
31. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid. Bishnoi M; Chopra K; Kulkarni SK Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):451-61. PubMed ID: 17988775 [TBL] [Abstract][Full Text] [Related]
32. Measuring movement disorders in antipsychotic drug trials: the need to define a new standard. Loonen AJ; van Praag HM J Clin Psychopharmacol; 2007 Oct; 27(5):423-30. PubMed ID: 17873670 [No Abstract] [Full Text] [Related]